世界卫生组织周一宣布暂停正在进行的羟氯喹如何影响住院COVID-19患者的试验，因为有人担心这种抗疟疾药物的安全性。唐纳德·特朗普总统说，这种药他至少服用了两周。

世卫组织总干事特德罗斯·阿德诺姆·格布雷耶苏斯说，世卫组织羟氯喹试验“暂时暂停”，同时“对安全性数据进行审查”。

在审判暂停的前一天，特朗普在接受辛克莱广播公司(Sinclair Broadcasting)采访时透露，他不再使用未经证实的冠状病毒治疗和预防方法，因为这种方法具有潜在的致命副作用，卫生专家和官员——包括特朗普政府内部的专家和官员——警告不要在医院或临床试验场所以外使用。

总统反复强调健康警告，同时对这种药物给予正面的——和不准确的——表扬。

2020年5月20日，犹他州普罗沃的洛克峡谷药房，一名制药技术人员正在倒出羟氯喹药丸。唐纳德·特朗普总统5月18日宣布，作为针对COVID-19的预防措施，他已经服用羟氯喹近两周了。

“完了，刚刚完。顺便说一句，我还在这里，”特朗普告诉辛克莱的沙尔利·阿特基森。“我听到了大量关于此事的报道...许多人认为它救了他们的命。”

特朗普在5月18日首次披露他正在服用羟氯喹，尽管该药曾被反复警告用于治疗冠状病毒。食品和药物管理局已经批准了它用于治疗疟疾，但是警告不要将其用于冠状病毒治疗或预防，并且仅应由住院患者或正在进行临床试验的患者使用。美国食品和药物管理局警告说，羟氯喹可能会导致心律失常。

特朗普的医生肖恩·康利(Sean Conley)上周表示，在与总统讨论了羟氯喹之后，“我们得出的结论是，治疗的潜在益处大于相关风险。”

Ghebreyesus在宣布暂停试验时，重复了美国卫生官员的指导，即不要自行服用该药物。

“我想重申的是，这些药物被公认为对患有自身免疫性疾病或疟疾的患者是安全的，”盖布雷耶苏斯说。

WHO Pauses Hydroxychloroquine Trial Amid Safety Concerns Day After Trump Says He Stopped Taking Controversial Medicine

The World Health Organization announced Monday that it was pausing an ongoing trial of how hydroxychloroquine impacts hospitalized COVID-19 patients over safety concerns of the anti-malaria drug—medicine that President Donald Trump said he was taking for at least two weeks.

A "temporary pause" of the WHO's hydroxychloroquine trial was instituted while "safety data is reviewed," said WHO Director General Tedros Adhanom Ghebreyesus.

The trial halt comes the day after Trump revealed in an interview with Sinclair Broadcasting that he was no longer taking the unproven coronavirus treatment and prevention method that health experts and officials—including within the Trump administration—have warned not to take outside hospital or clinical trial settings because of its potentially deadly side effects.

The president has repeatedly batted down health warnings while doling out positive—and inaccurate—praise for the drug.

A pharmacy tech pours out pills of Hydroxychloroquine at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020. President Donald Trump announced May 18 he has been taking hydroxychloroquine for almost two weeks as a preventative measure against COVID-19.

"Finished, just finished. And by the way, I'm still here," Trump told Sinclair's Sharyl Attkisson. "I've heard tremendous reports about it... Many people think it saved their lives."

Trump first disclosed he was taking hydroxychloroquine on May 18, despite the repeated warnings about the drug for coronavirus. The Food and Drug Administration has approved its usage for malaria but warned against using it for coronavirus treatment or prevention and that it should only be used by patients who are hospitalized or part of an ongoing clinical trial. Hydroxychloroquine could cause abnormal heart rhythms, among other things, the FDA cautions.

Trump's doctor, Sean Conley, stated last week that after discussing hydroxychloroquine with the president, "we concluded the potential benefit from treatment outweighed the relevant risks."

In his announcement of the trial pause, Ghebreyesus echoed U.S. health officials' guidance not to self-administer the drug.

"I wish to reiterate that these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria," Ghebreyesus said.